For generations, the pharmacy has been the first stop for Goan families dealing with common ailments. A seasonal cold, a sore throat, or a lingering cough rarely warranted a visit to the doctor. Instead, people would take a short walk to the local chemist and pick up a trusted bottle of cough syrup, sometimes the pharmacist making the choice easier.
That routine, however, has now been upended by the Union Health Ministry's amendments to the Drugs Rules, 1945. By removing "syrups" from the Schedule K exemptions, the government has effectively ended the easy over-the-counter availability of liquid oral cough remedies. What was once a simple five-minute purchase will now require a doctor's prescription, adding an extra layer to even the most routine healthcare decisions.
The reasons behind this regulatory system are compelling. In recent years, India's standing as the "pharmacy of the world" has suffered significant damage after contaminated pediatric medicines exported from the country were linked to the deaths of children in nations such as The Gambia and Uzbekistan. Closer to home, tragedy struck when at least 22 children in Madhya Pradesh died after consuming syrups contaminated with toxic industrial chemicals, including diethylene glycol (DEG), which caused acute kidney failure. Alongside concerns over contamination, regulators have long grappled with the widespread misuse of cough syrups containing ingredients such as codeine phosphate and dextromethorphan. These medicines, intended for legitimate treatment, have frequently found their way into recreational use, fuelling addiction and dependency under the cover of self-medication.
From a public health perspective, the government's decision is difficult to fault. The issue is about translating sound policy into everyday reality. For people already struggling with rising living costs, the new rules come with immediate practical consequences. A minor cough or common cold may now mean taking time off work, waiting in crowded clinics, and paying consultation fees simply to obtain a prescription for a routine remedy, fees that may cost more than the medicine itself. What was once a minor inconvenience could become a financial and logistical burden for many households.
The policy also raises concerns about the additional strain it may invite on an already stretched healthcare system. Requiring every mild respiratory complaint to be assessed by a qualified medical practitioner could significantly increase patient loads at primary health centres and district hospitals. Facilities already coping with staff shortages and long queues may find themselves spending crucial time treating minor viral infections rather than focusing on more serious health conditions. The challenge is even greater in rural and remote regions where a licensed doctor may not be readily available.
Ultimately, the success of this intervention will depend not only on regulation but also on thoughtful implementation. If enforcement relies solely on raids, penalties, and licence suspensions, authorities risk pushing the misuse of cough syrups into underground markets while creating frustration for ordinary consumers. A more balanced approach is needed which combines strict monitoring with public education. Digital prescription systems can help improve oversight, but they must be accompanied by awareness campaigns that encourage responsible medicine use. At the same time, safe and non-addictive alternatives, including tablets and approved herbal remedies, should remain easily available.
The government's objective is understandable and necessary, but the challenge lies in ensuring that the change does not create new hardships of its own. Striking the right balance between safety and accessibility will determine whether this policy becomes a model of public health.
